A R Artemenko, V G Abramov, T V Bozhenkina, Z N Konovalova, A N Korenko, D A Krasavina, A L Kurenkov, N V Latysheva, M V Naprienko, O R Orlova, E G Filatova, V S Shevchenko, P N Iakovleva
OBJECTIVE: To access the effect of Relatox, the first Russian botulinum toxin type A, in patients with chronic migraine (CM) and medication overuse (MO). MATERIAL AND METHODS: In phase IIIb single-blind randomized multicenter active-controlled parallel-group study, patients with CM were randomized to once intramuscular injections of Relatox ( n= 101) or onabotulinumtoxin A injections - Botox ( n= 108). This subgroup analysis evaluated the percentage of patients who transition from medication overuse to non overuse status from baseline; mean changes in the number of headache days, migraine headache days, acute headache medication intakes days, headache intensity, proportion of patients who had a ≥50% reduction in headache days, proportion of the patients with severe (≥60) Headache Impact Test-6 score and with a severe (≥21) MIDAS score in a 28-day periods in each treatment among patients with baseline acute medication overuse via repeated measures...
2023: Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova